<乌鸦传媒>Perioperative Chemo Enough in Esophageal Cancer? MAGIC/FLOT regimens yielded similar overall survival to multimodal CROSS regimen Jun 06, 2021
<乌鸦传媒>Small PFS Bump in Synovial Sarcoma With Novel Drug But questions raised over control arm and whether improvement represents a meaningful benefit Jun 05, 2021
<乌鸦传媒>PD-1 Inhibitor Shows Benefit in Nasopharyngeal Cancer Toripalimab plus first-line chemo improved survival in recurrent/metastatic disease Jun 03, 2021
<乌鸦传媒>Survival Boost With First-Line Immunotherapy for Esophageal Cancer Nivolumab plus ipilimumab or chemo offers new option for advanced, metastatic disease Jun 03, 2021
<乌鸦传媒>First-Line Chemo Plus Immunotherapy Falls Short in Bladder Cancer Adding pembrolizumab to cisplatin-based chemotherapy did not improve survival outcomes Jun 02, 2021
<乌鸦传媒>Radiation Speeds Up Biological Aging in Head and Neck Cancer Epigenetic age acceleration linked with greater inflammation and fatigue Jun 01, 2021
<乌鸦传媒>Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer No improvement in overall survival when added to cisplatin-containing chemotherapy Jun 01, 2021
<乌鸦传媒>Drug to Delay T1D Gets Tepid Endorsement by FDA Advisors Feelings mixed on safety and efficacy evidence for novel biologic May 28, 2021
<乌鸦传媒>Hospital at Home May Reduce Hospitalization, Costs for Cancer Patients Study demonstrated efficacy, cost-effectiveness of providing hospital-level services at home May 26, 2021
<乌鸦传媒>Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<乌鸦传媒>Potassium Acid Blocker No Better Than PPI for Artificial Gastric Ulcers Small Japanese trial found similar outcomes with both drugs May 25, 2021
<乌鸦传媒>Op-Ed: A Door Opens to Transform Cancer Care Incoming CMS Administrator Chiquita Brooks-LaSure brings hope to the cancer community May 25, 2021
<乌鸦传媒>Test Can Predict Death Risk With Adrenal Tumors This can help guide need for surgical intervention, researcher says May 24, 2021
<乌鸦传媒>RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers Responses to selpercatinib in almost half of tumors outside approved indications May 21, 2021
<乌鸦传媒>CHS Sues Thousands of Patients; Hospital Parking Fees Under Fire; Trump-Era Emails This past week in healthcare investigations May 19, 2021
<乌鸦传媒>Impressive Results With Lenvatinib in Challenging Tumors Multitargeted TKI achieves strong ORR in advanced gastroenteropancreatic NETs May 10, 2021
<乌鸦传媒>No Clarity for Role of Laser Therapy in Vulvar Lichen Sclerosus Mixed results from two small randomized clinical trials May 10, 2021
<乌鸦传媒>Is Dynamic AFP-R Key to Transplant Selection in Liver Cancer? Dynamic alpha-fetoprotein response improved prediction of patient outcomes May 05, 2021
<乌鸦传媒>What's Behind the Mysterious Chest Pain in Bladder Cancer Patient? Cardiomyopathy risks interrupting cancer treatment, worsening prognosis May 03, 2021
<乌鸦传媒>'It's a Straw-Man Argument': What We Heard This Week Quotable quotes from 乌鸦传媒's sources May 02, 2021
<乌鸦传媒>FDA Panel Splits on Anti-PD-1 Monotherapy in HCC All thumbs up for pembrolizumab, pending further data, but no such luck for nivolumab Apr 30, 2021
<乌鸦传媒>What to Do With a Rare, Aggressive Bladder Cancer Case authors lament scant information on treatments or outcomes Apr 26, 2021
<乌鸦传媒>PD-1 Inhibitor Approved for dMMR Endometrial Cancer Dostarlimab led to 42.3% response rate in recurrent/advanced disease Apr 22, 2021
<乌鸦传媒>Surveillance Spurned for Small Papillary Thyroid Tumors Nearly all head and neck surgeons would opt for lobectomy or total thyroidectomy Apr 22, 2021
<乌鸦传媒>Olympic Gold Medalist Nathan Adrian's Testicular Cancer The swimmer's diagnosis, treatment, and an "extra year" of pandemic prep for Toyko Apr 20, 2021
<乌鸦传媒>Another Player in Advanced Bladder Cancer Accelerated FDA approval of sacituzumab govitecan after chemo, immunotherapy Apr 14, 2021
<乌鸦传媒>Another FGFR Inhibitor Active in Bile Duct Cancers Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements Apr 13, 2021
<乌鸦传媒>Practice-Changing Results in Metastatic Uveal Melanoma Bispecific T cell-engaging tebentafusp reduces survival hazard by 50% Apr 10, 2021
<乌鸦传媒>No Cancer Risk With Commonly Used Blood Pressure Meds Largest analysis yet but definitive data remain elusive Apr 05, 2021
<乌鸦传媒>Anti-PD-L1 Flops in Locally Advanced Head and Neck Cancer No PFS benefit from adding avelumab to chemoradiation, hazard ratio favored placebo Apr 02, 2021
<乌鸦传媒>A Win for Adjuvant Immunotherapy in Esophageal Cancer And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
<乌鸦传媒>Model: Give COVID-19 Vaccine to All Patients Before Surgery Prioritizing surgical patient population could avert more COVID deaths Mar 25, 2021
<乌鸦传媒>Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
<乌鸦传媒>Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancer Chemo prevented relapse but did not improve survival, no benefit from radiotherapy Mar 23, 2021
<乌鸦传媒>Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
<乌鸦传媒>Hormonal IUD Shows Promise in Early Endometrial Cancer Regression seen in 82% of women with precancerous lesions Mar 21, 2021
<乌鸦传媒>Practice-Changing Trial in Second-Line Endometrial Cancer Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy Mar 19, 2021
<乌鸦传媒>Class of Cancer Drug Linked to Aneurysms, Artery Dissections Database analysis finds more reports than expected with antiangiogenic drugs Mar 18, 2021
<乌鸦传媒>Acupuncture Tops Usual Care for Pain in Cancer Survivors Two types of acupuncture proved superior, with one better than the other Mar 18, 2021
<乌鸦传媒>Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
